Mostrar el registro sencillo del ítem

dc.contributor.authorAguirre-Franco C
dc.contributor.authorTorres-Duque C.A
dc.contributor.authorSalazar G
dc.contributor.authorCasas A
dc.contributor.authorJaramillo C
dc.contributor.authorGonzalez-Garcia M.
dc.date.accessioned2024-11-01T14:34:30Z
dc.date.available2024-11-01T14:34:30Z
dc.date.issued2024
dc.identifier.issn25310429
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85124379914&doi=10.1016%2fj.pulmoe.2021.12.006&partnerID=40&md5=e40b9d16442adf4d7d7b92b9f4c50a44
dc.identifier.urihttp://hdl.handle.net/10818/62186
dc.description.abstractBackground: Pulmonary hypertension (PH) is associated with poor prognosis for patients with chronic obstructive pulmonary disease (COPD). Most of the knowledge about PH in COPD has been generated at sea level, with limited information associated with high altitude (HA). Objectives: To assess the prevalence and severity of PH in COPD patients living in a HA city (2,640 m). Methods: Cross-sectional study in COPD patients with forced expiratory volume in the first second / forced vital capacity ratio (FEV1/FVC) post-bronchodilator <0,7. Transthoracic echocardiography (TTE), spirometry, carbon monoxide diffusing capacity, and arterial blood gasses tests were performed. Patients were classified according to the severity of airflow limitation. PH was defined by TTE as an estimated systolic pulmonary artery pressure (sPAP) > 36 mmHg or indirect PH signs; severe PH as sPAP > 60 mmHg; and disproportionate PH as an sPAP > 60 mmHg with non-severe airflow limitation (FEV1 > 50% predicted). Results: We included 176 COPD patients. The overall estimated prevalence of PH was 56.3% and the likelihood of having PH increased according to airflow-limitation severity: mild (31.6%), moderate (54.9%), severe (59.6%) and very severe (77.8%) (p = 0.038). The PH was severe in 7.3% and disproportionate in 3.4% of patients. Conclusions: The estimated prevalence of PH in patients with COPD at HA is high, particularly in patients with mild to moderate airflow limitation, and greater than that described for COPD patients at low altitude. These results suggest a higher risk of developing PH for COPD patients living at HA compared to COPD patients with similar airflow limitation living at low altitude. © 2022 Sociedade Portuguesa de Pneumologiaen
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherPulmonologyes_CO
dc.relation.ispartofseriesPulmonology Vol. 30 N° 3
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subject.otherBronchodilating agenten
dc.subject.otherCarbon monoxideen
dc.subject.otherAgeden
dc.subject.otherAltitudeen
dc.subject.otherArterial gasen
dc.subject.otherArticleen
dc.subject.otherCross-Sectional Studyen
dc.subject.otherDisease severityen
dc.subject.otherEchocardiographyen
dc.titlePrevalence of pulmonary hypertension in copd patients living at high altitudeen
dc.typejournal articlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.1016/j.pulmoe.2021.12.006


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International